Jump to main content
Jump to site search

Issue 9, 2010
Previous Article Next Article

An integrative model for vascular endothelial growth factor A as a tumour biomarker

Author affiliations

Abstract

Vascular endothelial growth factor A (VEGF-A) and its cognate receptors are central to the regulation of angiogenesis in both physiological and pathological states. In cancer, local tumour hypoxia stimulates VEGF-A synthesis and VEGF-A levels are subsequently elevated in a wide variety of cancers. VEGF-A thus has enormous potential as a diagnostic and prognostic biomarker of disease status. The justification of VEGF-A as a biomarker has not yet been achieved, primarily due to our lack of understanding of its multiple splice variants and its spatio-temporal distribution. Here we highlight how recent technological advancements and kinetic-dynamic modelling could be used towards validating VEGF-A as a biomarker for clinical use in human disease management.

Graphical abstract: An integrative model for vascular endothelial growth factor A as a tumour biomarker

Back to tab navigation

Publication details

The article was received on 17 Feb 2010, accepted on 20 Jul 2010 and first published on 20 Aug 2010


Article type: Review Article
DOI: 10.1039/C0IB00008F
Citation: Integr. Biol., 2010,2, 397-407
  •   Request permissions

    An integrative model for vascular endothelial growth factor A as a tumour biomarker

    A. M. Latham, C. Molina-París, S. Homer-Vanniasinkam and S. Ponnambalam, Integr. Biol., 2010, 2, 397
    DOI: 10.1039/C0IB00008F

Search articles by author

Spotlight

Advertisements